Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins

Abstract

Purpose of Review The accumulation of triglyceride-rich lipoproteins (TRLs) in plasma in patients with familial chylomicronaemia syndrome (FCS) or severe hypertriglyceridemia is associated with an increased risk of potentially life-threatening pancreatitis. Elevated TRL levels have also been suggested to contribute to atherosclerotic cardiovascular disease (ASCVD). This review provides the latest progress that has been made in this field of research. Recent Findings Apolipoprotein C-III and angiopoietin-like protein 3 play key roles in the metabolism of TRLs. Targeting their production in the liver or their presence in the circulation effectively reduces triglycerides in patients with FCS or severe hypertriglyceridemia. Attempts to reduce triglyceride synthesis in the small intestine have been halted. Early studies with a fibroblast growth factor 21 agonist have shown to reduce plasma triglycerides and hepatic steatosis and improve glucose homeostasis. Summary New drugs have recently been shown to effectively reduce plasma triglycerides which render hope for treating the risk of pancreatitis. Studies that have just been initiated will learn whether this unmet clinical will be met. It is too early to evaluate the potential of these drugs to reduce the risk of atherosclerosis through the reduction of triglycerides.

The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus

“…Diabetic dyslipidemia, which is characterized by elevated triglycerides, low HDL-C, and a predominance of small-dense LDL particles, is the most significant clinical manifestation of this interaction [ 125 ]. Triglyceride-rich lipoproteins (TRLs) tend to accumulate more frequently in diabetic dyslipidemia [ 126 ]. The combination of a defect, excessive production of TRL-apoB-100, also known as very low-density lipoprotein (VLDL, primarily VLDL1) from the liver, and removal of TRL-apoB-48, also known as chylomicrons, from the gut results in diabetic dyslipidemia [ 127 ].…”

Recent advances of mechanosensitive genes in vascular endothelial cells for the formation and treatment of atherosclerosis

“… 1 , 2 , 3 One of the early markers of atherosclerosis is endothelial dysfunction, which leads to infiltration of low-density lipoprotein (LDL) into the vascular medium, accompanied by monocyte recruitment and abnormal phagocytosis. 4 , 5 , 6 Macroscopically, vulnerable plaques (characterized by plaques with large necrotic cores covered by thin fibrous caps) form and rupture, thereby leading to arterial thrombosis 7 , 8 ( Fig. 1 and Table 1 ).…”

Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis

“…The functions of FGF21 have spurred several research groups to test the effects of treatment with FGF21 or developed analogs on models of metabolic diseases such as obesity and diabetes (20). In preclinical trials, using FGF21 reduced weight gain and fat and lean mass, independent of food and water consumption, which increased in some studies (21)(22)(23)(24)(25).…”